ExonHit extends research deal with Allergan to 2009, adds neurodegenerative diseases

By E. Janene Geiss

Philadelphia, Sept. 19 - ExonHit Therapeutics SA said Tuesday that it has extended its strategic collaboration with Allergan, Inc. to identify, develop and commercialize drugs targeted to treat neurodegenerative diseases, pain and ophthalmology based on the positive preclinical trial results achieved to date.

Since 2003, ExonHit and Allergan have twice extended their collaboration. The latest deal extends the term until December 2009 and will now include research of neurodegenerative diseases such as Parkinson's disease, along with Alzheimer's disease, ALS, pain and ophthalmology, the companies said in a news release.

The payment structure was revised to increase milestone and royalty payments on the sale of collaboration drugs and increase research and development funding. ExonHit, a Paris-based biotechnology company, also received a payment upon signing this new agreement.

Under terms of the collaboration, ExonHit receives financial support in the form of ongoing research and development payments as well as payments for drug candidates achieving certain development milestones.

Additionally, ExonHit will receive co-development and co-commercialization options in therapeutic areas outside of strategic areas of Allergan, an Irvine, Calif., specialty pharmaceutical company. In cases of co-development and co-commercialization, ExonHit will receive profit-sharing on commercialized drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.